<doc>
  <docmeta id="113s348is">
    <bill congress="113" type="s" number="348" version="is"/>
    <revision size="30765" annotations="0" id="5" commit-time="2013-05-28T22:32:07Z" status="complete" committer="mbohmer" doc="113s348is/5.xml">
      <description description="Markup copied from completed documents">Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-Senate" public-private="public">
	<form>
		<distribution-code display="yes">II</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>S. 348</legis-num>
		<current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber>
		<action>
			<action-date date="20130214">February 14, 2013</action-date>
			<action-desc>
        <sponsor name-id="S176">Mr. Rockefeller</sponsor> (for
			 himself, <cosponsor name-id="S338">Mr. Manchin</cosponsor>, and
			 <cosponsor name-id="S331">Mrs. Gillibrand</cosponsor>) introduced the following
			 bill; which was read twice and referred to the
			 <committee-name committee-id="SSHR00">Committee on Health, Education, Labor,
			 and Pensions</committee-name>
      </action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To provide for increased Federal oversight of
		  prescription opioid treatment and assistance to States in reducing opioid
		  abuse, diversion, and deaths.</official-title>
	</form>
	<legis-body>
		<section id="S1" section-type="section-one">
      <enum>1.</enum>
      <header>Short
			 title</header>
      <text display-inline="no-display-inline">This Act may be cited as
			 the <quote>
          <short-title>Prescription Drug Abuse Prevention
			 and Treatment Act of 2013</short-title>
        </quote>.</text>
		</section>
    <section id="id93CA301ED18941ED985CC2C372C98A68">
      <enum>2.</enum>
      <header>Findings</header>
      <text display-inline="no-display-inline">
        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref> makes the following
			 findings:</text>
			<paragraph id="ID2dc9bf3a2f3e47158270b05adc345f25">
        <enum>(1)</enum>
        <text>Nonmedical use of prescription pain relievers is a matter of increasing public health concern. According to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7522">Substance Abuse and Mental Health Services Administration</cato:entity-ref>, the proportion of all substance abuse treatment admissions aged 12 or older that reported any pain reliever abuse increased more than 400 percent between 1998 and 2008, from 2.2 to 9.8 percent.</text>
			</paragraph>
      <paragraph id="ID3f35bf3169b44513ae3c70104f339758">
        <enum>(2)</enum>
        <text>In 2008, among
			 the population of the United States aged 12 or older, nonmedical use of
			 prescription pain relievers was the second most prevalent type of illicit drug
			 use, after marijuana use.</text>
			</paragraph>
      <paragraph id="IDe15aa0a8a1494fcc930490191e23dc41">
        <enum>(3)</enum>
        <text>When used
			 properly under medical supervision, prescription opiates enable individuals
			 with chronic pain to lead productive lives. However, when taken without a
			 physician’s oversight and direction, opiates can cause serious adverse health
			 effects, resulting in dependence, abuse, and death.</text>
			</paragraph>
      <paragraph id="ID1b76f47a0c744f5aab1e72cd13be04d5">
        <enum>(4)</enum>
        <text>As with any
			 controlled substance, there is a risk of abuse of methadone and other
			 opiates.</text>
			</paragraph>
      <paragraph id="ID58fcb3d39a0f4a05993ce8f40a7bdc73">
        <enum>(5)</enum>
        <text>Methadone is an
			 extensively tested, federally approved, and widely accepted method of treating
			 addiction to prescription pain relievers or opiates.</text>
			</paragraph>
      <paragraph id="ID8c57997e0f23465980fa1eb202644d4a">
        <enum>(6)</enum>
        <text>For more than 30
			 years, this synthetic prescription drug has been used for pain management and
			 treatment for addiction to heroin, morphine, and other opioid drugs.</text>
			</paragraph>
      <paragraph id="ID44f01911b33c4201baddc80f1b105cf0">
        <enum>(7)</enum>
        <text>The efficacy and
			 lower cost of methadone has resulted in its being prescribed for pain
			 management.</text>
			</paragraph>
      <paragraph id="ID580c212c01c54173b168f625cbbcaa75">
        <enum>(8)</enum>
        <text>Prescriptions for
			 methadone have increased by nearly 700 percent from 1998 through 2006.</text>
			</paragraph>
      <paragraph id="ID6ea17e2464ab478ca8a8fecf6b7f0d0e">
        <enum>(9)</enum>
        <text>According to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7523">Centers for Disease Control and Prevention</cato:entity-ref>, the number of poisoning deaths involving methadone increased nearly 7-fold from almost 790 in 1999 to almost 5,420 in 2006, which is the most rapid increase among opioid analgesics and other narcotics involved in poisoning deaths.</text>
			</paragraph>
      <paragraph id="ID44bab3393944435d988a6aecfffa4473">
        <enum>(10)</enum>
        <text>The age-specific
			 rates of methadone death are higher for persons age 35 to 44 and 45 to 54 than
			 for other age groups. However, the rate of methadone deaths in younger
			 individuals (age 15 to 24) increased 11-fold from 1999 through 2005.</text>
			</paragraph>
      <paragraph id="ID94ca37e185b24b88a7d05035e08ed132">
        <enum>(11)</enum>
        <text>Deaths from
			 methadone and other opiates may actually be underreported. There is no
			 comprehensive database of drug-related deaths in the United States.</text>
			</paragraph>
      <paragraph id="ID2e22679be11d4a4a9c548abdf59dba1a">
        <enum>(12)</enum>
        <text>The lack of
			 standardized reporting by Medical Examiners precludes a uniform definition of
			 <term>cause of death</term> on death certificates.</text>
			</paragraph>
      <paragraph id="ID3db99d4587f04bceba2fe0cf7de6dda6">
        <enum>(13)</enum>
        <text>The <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Controlled Substances Act">Controlled Substances Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/21/801/etseq">21 U.S.C. 801 et seq.</cato:entity-ref>)</cato:entity> requires that every person who dispenses or who proposes to dispense controlled narcotics, including methadone, whether for pain management or opioid treatment obtain a registration from <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1524">Drug Enforcement Administration</cato:entity-ref>. Unfortunately there is no requirement as a condition of receiving the registration that these practitioners receive any education on the use of these controlled narcotics, including methadone.</text>
			</paragraph>
      <paragraph id="ID77d32a8edb754c18a05c10e779aed9c5">
        <enum>(14)</enum>
        <text>Current Federal
			 oversight of methadone and other opioids is inadequate to address the growing
			 number of opioid-related overdoses and deaths.</text>
			</paragraph>
      <paragraph id="ID237979d1195f4aec8be474848e971538">
        <enum>(15)</enum>
        <text>Federal
			 legislation is needed to avert opioid abuse, misuse, and death, without
			 reducing patient access to needed care.</text>
			</paragraph>
    </section>
    <section commented="no" display-inline="no-display-inline" id="id859C9075063D4BC7885E04EAD9A238CC">
      <enum>3.</enum>
      <header>Consumer
			 education campaign</header>
      <text display-inline="no-display-inline">
        <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Public Health Service Act/t:V/pt:A">Part A of title V of the Public Health Service Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/42/290aa/etseq">42 U.S.C. 290aa et seq.</cato:entity-ref>)</cato:entity> is amended by adding at the end the following:</text>
			<quoted-block display-inline="no-display-inline" id="idDE775F7904274E1FB7FA328F22E01F2F" style="OLC">
				<section commented="no" display-inline="no-display-inline" id="id9B932E7488614EF0A559EBE97A0A4D20">
          <enum>506C.</enum>
          <header>Consumer
				education campaign</header>
					<subsection id="idCD1171A5FDF4459D813EF0D832BE3726">
            <enum>(a)</enum>
            <header>In
				general</header>
            <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7522">Administrator</cato:entity-ref> shall award grants to States and nonprofit entities for the purpose of conducting culturally sensitive consumer education about opioid abuse, including methadone abuse. Such education shall include information on the dangers of opioid abuse, how to prevent opioid abuse including through safe disposal of prescription medications and other safety precautions, and detection of early warning signs of addiction.</text>
					</subsection>
          <subsection id="id69DE285753E7465499B111432278B37D">
            <enum>(b)</enum>
            <header>Eligibility</header>
            <text>To
				be eligible to receive a grant under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:506C/ss:a" proposed="true">subsection (a)</cato:entity-ref>, an entity shall—</text>
						<paragraph id="idB8DBF9E6914D4B5D9F3B95CB5257C57F">
              <enum>(1)</enum>
              <text>be a State or
				nonprofit entity; and</text>
						</paragraph>
            <paragraph id="id0D1E5FE29D3249D7820F09AA21A5F6E3">
              <enum>(2)</enum>
              <text>submit to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7522">Administrator</cato:entity-ref> an application at such time, in such manner, and containing such information as the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7522">Administrator</cato:entity-ref> may require.</text>
						</paragraph>
          </subsection>
          <subsection id="idE68C7ED2DD3B479FA69B24501D38D7C1">
            <enum>(c)</enum>
            <header>Priority</header>
            <text>In awarding grants under this section, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7522">Administrator</cato:entity-ref> shall give priority to applicants that are States or communities with a high incidence of abuse of methadone and other opioids, and opioid-related deaths.</text>
					</subsection>
          <subsection id="id983ECE9BF57A4FDEAF55F458E7A03BAF">
            <enum>(d)</enum>
            <header>Evaluations</header>
            <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7522">Administrator</cato:entity-ref> shall develop a process to evaluate the effectiveness of activities carried out by grantees under this section at reducing abuse of methadone and other opioids.</text>
					</subsection>
          <subsection id="idB618761B3C3442C4A4D4918F6E1E82D5">
            <enum>(e)</enum>
            <header>Authorization
				of appropriations</header>
            <text>
              <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="auth-auth-approp">There is authorized to be appropriated <cato:property name="purpose">to carry
				out <cato:entity-ref entity-type="act" value="Public Health Service Act/s:506C" proposed="true">this section</cato:entity-ref>
                </cato:property> <cato:funds-and-year amount="15000000" year="2014, 2015, 2016, 2017, 2018">$15,000,000 for each of fiscal years 2014 through
				2018</cato:funds-and-year>.</cato:entity>
            </text>
					</subsection>
        </section>
        <after-quoted-block>.</after-quoted-block>
      </quoted-block>
		</section>
    <section id="idB841E52D5F6F4C5EA31A72473250C399">
      <enum>4.</enum>
      <header>Practitioner
			 education</header>
			<subsection id="id8B7D6D827EBE4EE288341FF5AC75B770">
        <enum>(a)</enum>
        <header>Education
			 requirements</header>
				<paragraph id="idF40363F4D34E470780344E96B276E6DC">
          <enum>(1)</enum>
          <header>Registration
			 consideration</header>
          <text>
            <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Controlled Substances Act/s:303/ss:f">Section 303(f) of the Controlled Substances Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/21/823/f">21 U.S.C. 823(f)</cato:entity-ref>)</cato:entity> is amended by inserting after <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:303/ss:f/p:5">paragraph (5)</cato:entity-ref> the following:</text>
					<quoted-block display-inline="no-display-inline" id="id9A222539540F431D87F17F65952099CE" style="OLC">
						<paragraph id="idF8549B0EB29E4311940BE308F7F37B4F">
              <enum>(6)</enum>
              <text>The applicant's compliance with the training requirements described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:303/ss:g/p:3" proposed="true">subsection (g)(3)</cato:entity-ref> during any previous period in which the applicant has been subject to such training requirements.</text>
						</paragraph>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
				</paragraph>
        <paragraph id="id4A0FAEE6CBFB4174A5372A0555091A92">
          <enum>(2)</enum>
          <header>Training
			 requirements</header>
          <text>
            <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Controlled Substances Act/s:303/ss:g">Section 303(g) of the Controlled Substances Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/21/823/g">21 U.S.C. 823(g)</cato:entity-ref>)</cato:entity> is amended by adding at the end the following:</text>
					<quoted-block display-inline="no-display-inline" id="idE0EC8BC038034886934D991E8F159BBE" style="OLC">
						<paragraph id="id9E8D667540424AEE8FBF71B54FAE6619" indent="up1">
              <enum>(3)</enum>
              <subparagraph commented="no" display-inline="yes-display-inline" id="id152D303E91B4453A898ECD539E1ED932">
                <enum>(A)</enum>
                <text>To be registered to prescribe or otherwise dispense methadone or other opioids, a practitioner described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:303/ss:g/p:1">paragraph (1)</cato:entity-ref> shall comply with the 16-hour training requirement of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:303/ss:g/p:3/sp:B" proposed="true">subparagraph (B)</cato:entity-ref> at least once during each 3-year period.</text>
							</subparagraph>
              <subparagraph commented="no" display-inline="no-display-inline" id="id820E7B47850244D8B1A61DF3213D5DFC" indent="up1">
                <enum>(B)</enum>
                <text>The training requirement of this
				subparagraph is that the practitioner has completed not less than 16 hours of
				training (through classroom situations, seminars at professional society
				meetings, electronic communications, or otherwise) with respect to—</text>
								<clause commented="no" display-inline="no-display-inline" id="idC7B4700CBEED40EE9991EDA2EBF335F2">
                  <enum>(i)</enum>
                  <text>the treatment and management of
				opioid-dependent patients;</text>
								</clause>
                <clause commented="no" display-inline="no-display-inline" id="idA08A553D66CC4119AD1E80A9AF5FDC12">
                  <enum>(ii)</enum>
                  <text>pain management treatment guidelines;
				and</text>
								</clause>
                <clause commented="no" display-inline="no-display-inline" id="id875E2BC82E6E487AB3C9EBD983EBC53A">
                  <enum>(iii)</enum>
                  <text>early detection of opioid addiction,
				including through such methods as Screening, Brief Intervention, and Referral
				to Treatment (SBIRT),</text>
								</clause>
                <continuation-text continuation-text-level="subparagraph" indent="subsection">that is provided by the American Society of Addiction
				Medicine, the American Academy of Addiction Psychiatry, the American Medical
				Association, the American Osteopathic Association, the American Psychiatric
				Association, the American Academy of Pain Management, the American Pain
				Society, the American Academy of Pain Medicine, the American Board of Pain
				Medicine, the American Society of Interventional Pain Physicians, or any other
				organization that the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> determines is appropriate for purposes of this
				subparagraph.</continuation-text>
              </subparagraph>
            </paragraph>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
				</paragraph>
      </subsection>
      <subsection id="id2564391857604306A72223BDF466ED32">
        <enum>(b)</enum>
        <header>Requirements
			 for participation in opioid treatment programs</header>
        <text>Effective July 1, 2014, a physician practicing in an opioid treatment program shall comply with the requirements of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:303/ss:g/p:3" proposed="true">section 303(g)(3) of the Controlled Substances Act</cato:entity-ref> (as added by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Prescription Drug Abuse Prevention and Treatment Act of 2013/s:4/ss:a" proposed="true">subsection (a)</cato:entity-ref>) with respect to required minimum training at least once during each 3-year period.</text>
			</subsection>
      <subsection id="id238B39EE94E9471C8792F33FC619DDFC">
        <enum>(c)</enum>
        <header>Definition</header>
        <text>In
			 this section, the term <term>opioid treatment program</term> has the meaning
			 given such term in section 8.2 of title 42, Code of Federal Regulations (or any
			 successor regulation).</text>
			</subsection>
      <subsection id="idDC49608A126E4A26BA9278025930F4CC">
        <enum>(d)</enum>
        <header>Funding</header>
        <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1524">Drug Enforcement Administration</cato:entity-ref> shall fund the enforcement of the requirements specified in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:303/ss:g/p:3" proposed="true">section 303(g)(3) of the Controlled Substances Act</cato:entity-ref> (as added by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Prescription Drug Abuse Prevention and Treatment Act of 2013/s:4/ss:a" proposed="true">subsection (a)</cato:entity-ref>) through the use of a portion of the licensing fees paid by controlled substance prescribers under the <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Controlled Substances Act">Controlled Substances Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/21/801/etseq">21 U.S.C. 801 et seq.</cato:entity-ref>)</cato:entity>.</text>
			</subsection>
    </section>
    <section commented="no" id="id27CB900D3A6E4F658AFECC9247C17B7F">
      <enum>5.</enum>
      <header>Moratorium on
			 methadone hydrochloride tablets</header>
			<subsection commented="no" id="idE997E7A25325438F8ED0A7BFB1525428">
        <enum>(a)</enum>
        <header>In
			 general</header>
        <text>Notwithstanding any other provision of law, during the period beginning on the date of enactment of this Act and ending on the date described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Prescription Drug Abuse Prevention and Treatment Act of 2013/s:5/ss:b" proposed="true">subsection (b)</cato:entity-ref>, no individual or entity may prescribe or otherwise dispense a 40-mg diskette of methadone unless such prescription or dispensation is consistent with the methadone 40-mg diskette policy of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1524">Drug Enforcement Administration</cato:entity-ref> as in effect on the date of enactment of this Act, except that such prohibition shall extend to hospitals unless such hospitals provide for direct patient supervision with respect to such methadone.</text>
			</subsection>
      <subsection commented="no" id="id3D1E38203B7645C5B0B63464ADEE2B4C">
        <enum>(b)</enum>
        <header>Ending date of
			 moratorium</header>
        <text>The moratorium under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Prescription Drug Abuse Prevention and Treatment Act of 2013/s:5/ss:a" proposed="true">subsection (a)</cato:entity-ref> shall cease to have force and effect—</text>
				<paragraph commented="no" id="IDe462d077951d40f78696ca8051f2195b">
          <enum>(1)</enum>
          <text>on the date that the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" proposed="true" value="Controlled Substances Clinical Standards Commission">Controlled Substances Clinical Standards Commission</cato:entity-ref> publishes in the Federal Register dosing guidelines for all forms of methadone, in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:506D/ss:b/p:1/sp:A" proposed="true">section 506D(b)(1)(A) of the Public Health Service Act</cato:entity-ref> (as added by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Prescription Drug Abuse Prevention and Treatment Act of 2013/s:7" proposed="true">section 7</cato:entity-ref>); and</text>
				</paragraph>
        <paragraph commented="no" id="ID37b785b5659d41368afcbebcb0db4d73">
          <enum>(2)</enum>
          <text>if, as part of such dosing guidelines, such <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Controlled Substances Clinical Standards Commission" proposed="true">Commission</cato:entity-ref> finds that 40-mg diskettes of methadone are safe and clinically appropriate.</text>
				</paragraph>
      </subsection>
    </section>
    <section id="id73F22E1951554761BB7056E0AF6BE6E8">
      <enum>6.</enum>
      <header>Operation of
			 opioid treatment programs</header>
      <text display-inline="no-display-inline">
        <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Controlled Substances Act/s:303">Section 303 of the Controlled Substances Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/21/823">21 U.S.C. 823</cato:entity-ref>)</cato:entity> is amended by adding at the end the following:</text>
			<quoted-block display-inline="no-display-inline" id="id8579CC95626B4A0399CD805B617B784B" style="OLC">
				<subsection id="idCEE928D8EF0C4345A7D3E1591AEF534B">
          <enum>(i)</enum>
          <paragraph commented="no" display-inline="yes-display-inline" id="id281A6725667D4C1B93DBB589C5730FCF">
            <enum>(1)</enum>
            <text>An opioid treatment
				program that is registered under this section, and that closes for business on
				any weekday or weekend day, including a Federal or State holiday, shall comply
				with the requirements of this subsection.</text>
					</paragraph>
          <paragraph id="idAE88C13C77C54402B2669108CBD78672" indent="up1">
            <enum>(2)</enum>
            <text>The program shall make acceptable
				arrangements for each patient who is restricted, by Federal regulation or
				guideline or by the determination of the program medical director, from having
				a take home dose of a controlled substance related to the treatment involved,
				to receive a dose of that substance under appropriate supervision during the
				closure.</text>
					</paragraph>
          <paragraph id="id069B4EA4588A4F0D94CA844982651774" indent="up1">
            <enum>(3)</enum>
            <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7522">Administrator of the Substance Abuse and Mental Health Services Administration</cato:entity-ref> shall issue a notice that references regulations on acceptable arrangements under this subsection, or shall promulgate regulations on such acceptable arrangements.</text>
					</paragraph>
        </subsection>
        <after-quoted-block>.</after-quoted-block>
      </quoted-block>
		</section>
    <section id="idCCDC3FAE176A4DC0BA518101897CE8E7">
      <enum>7.</enum>
      <header>Establishment of
			 the Controlled Substances Clinical Standards Commission</header>
      <text display-inline="no-display-inline">
        <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Public Health Service Act/t:V/pt:A">Part A of title V of the Public Health Service Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/42/290aa/etseq">42 U.S.C. 290aa et seq.</cato:entity-ref>)</cato:entity>, as amended by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Prescription Drug Abuse Prevention and Treatment Act of 2013/s:3" proposed="true">section 3</cato:entity-ref>, is further amended by adding at the end the following:</text>
			<quoted-block display-inline="no-display-inline" id="id47DBD7E466AF40D1AE0C7344265B5FC9" style="OLC">
				<section id="id8D978544DADC4A919E70AA51EA240A57">
          <enum>506D.</enum>
          <header>Establishment
				of the Controlled Substances Clinical Standards Commission</header>
					<subsection id="id37F25F82567E470DBE3470AC504F8054">
            <enum>(a)</enum>
            <header>In
				general</header>
            <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall establish a <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Controlled Substances Clinical Standards Commission" proposed="true">Controlled Substances Clinical Standards Commission</cato:entity-ref> (referred to in this section as the <term>Commission</term>), to be composed of representatives from the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7522">Administration</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7523">Centers for Disease Control and Prevention</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-parent-id="7529" value="Pain Management Consortia">Pain Management Consortia of the National Institutes of Health</cato:entity-ref>, and other agencies that the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may deem necessary, to develop—</text>
						<paragraph id="ID800b1010ec4246929fb3d40b58bd59dd">
              <enum>(1)</enum>
              <text>appropriate and safe dosing guidelines for all forms of methadone, including recommendations for maximum daily doses of all forms as provided for in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:506D/ss:b/p:1" proposed="true">subsection (b)(1)</cato:entity-ref>;</text>
						</paragraph>
            <paragraph id="IDe3a052bfba5c461c838445ee11233157">
              <enum>(2)</enum>
              <text>benchmark guidelines for the reduction of methadone abuse, as provided for in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:506D/ss:b/p:2" proposed="true">subsection (b)(2)</cato:entity-ref>;</text>
						</paragraph>
            <paragraph id="idDE58901A0F774ADCA64800960A8D19D5">
              <enum>(3)</enum>
              <text>appropriate
				conversion factors for use by health care providers in transitioning patients
				from one opioid to another;</text>
						</paragraph>
            <paragraph id="IDecb170ba5f80493a9670418c361e06b0">
              <enum>(4)</enum>
              <text>specific guidelines for initiating pain management with methadone that prescribing practitioners shall comply with in order to meet certification requirements set forth in <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                  <cato:entity-ref entity-type="act" value="Controlled Substances Act/pt:C">part C of the Controlled Substances Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/21/821/etseq">21 U.S.C. 821 et seq.</cato:entity-ref>)</cato:entity>; and</text>
						</paragraph>
            <paragraph id="ID70982340c51643e3adb1e0f117a6ef56">
              <enum>(5)</enum>
              <text>patient and
				practitioner education guidelines for both methadone maintenance therapy and
				pain management that apply to safe and effective use and include
				detoxification.</text>
						</paragraph>
          </subsection>
          <subsection id="id4FFF1BF907F740A39A78F621AF3E7C98">
            <enum>(b)</enum>
            <header>Guidelines</header>
						<paragraph id="id89F2658BFB3C437394AB1E8B6E2E1C01">
              <enum>(1)</enum>
              <header>Publication of
				dosing guidelines</header>
							<subparagraph id="id1E1D5D5D47B442EA9BC4027C255BE12C">
                <enum>(A)</enum>
                <header>In
				general</header>
                <text>Not later than 2 years after the date of enactment of this section, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Controlled Substances Clinical Standards Commission" proposed="true">Commission</cato:entity-ref> established under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:506D/ss:a" proposed="true">subsection (a)</cato:entity-ref> shall publish in the Federal Register—</text>
								<clause id="idA91308491420409B964A0594466D159D">
                  <enum>(i)</enum>
                  <text>safe and
				clinically appropriate dosing guidelines for all forms of methadone used for
				both pain management and opioid treatment programs, including recommendations
				for maximum daily doses of all forms, including recommendations for the
				induction process for patients who are newly prescribed methadone;</text>
								</clause>
                <clause id="idE447518F9AD24A318B6334CFB40D3537">
                  <enum>(ii)</enum>
                  <text>requirements for
				individual patient care plans, including initial and follow-up patient physical
				examination guidelines, and recommendations for screening patients for chronic
				or acute medical conditions that may cause an immediate and adverse reaction to
				methadone;</text>
								</clause>
                <clause id="idBE6BC83666B84DD1B4253D65408DFB50">
                  <enum>(iii)</enum>
                  <text>appropriate
				conversion factors for use by health care providers in transitioning patients
				from one opioid to another;</text>
								</clause>
                <clause id="id27FEE87FB0CB4CAC8D68A8C7329BE4B8">
                  <enum>(iv)</enum>
                  <text>specific guidelines for initiating pain management with methadone, that prescribing physicians or other clinicians shall comply with in order to meet <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1524">Drug Enforcement Administration</cato:entity-ref> certification and re-certification requirements; and</text>
								</clause>
                <clause id="idB1CCCCB32C9D4AFFA85ECE210F1DFD1A">
                  <enum>(v)</enum>
                  <text>consensus
				guidelines for pain management with prescription opioid drugs.</text>
								</clause>
              </subparagraph>
              <subparagraph id="idF2AFA0B6014443EDA3590B3F4A3F5345">
                <enum>(B)</enum>
                <header>Updating of
				guidelines</header>
                <text>Not later than 3 years after the publication of guidelines under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:506D/ss:b/p:1/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>, and at least every 3 years thereafter, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Controlled Substances Clinical Standards Commission" proposed="true">Commission</cato:entity-ref> shall update such guidelines.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="id643ECE2E30C9488FBBFEE333CC287BAB">
              <enum>(2)</enum>
              <header>Publication of
				benchmark guidelines</header>
							<subparagraph id="idED0E029737B2496E9882A4C9C191ECB9">
                <enum>(A)</enum>
                <header>In
				general</header>
                <text>Not later than 3 years after the date of enactment of this section, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Controlled Substances Clinical Standards Commission" proposed="true">Commission</cato:entity-ref> established under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:506D/ss:a" proposed="true">subsection (a)</cato:entity-ref> shall publish in the Federal Register—</text>
								<clause id="id3D3D366B60EC4110A30C0EDECF78965D">
                  <enum>(i)</enum>
                  <text>the initial
				benchmark guidelines for the reduction of methadone abuse to be used—</text>
									<subclause id="id4AD8EEC17CEE4247800B5A33D58CD5DA">
                    <enum>(I)</enum>
                    <text>by opioid
				treatment programs in providing methadone therapy; and</text>
									</subclause>
                  <subclause id="id5F1762E54BB14F27955C7638575D513C">
                    <enum>(II)</enum>
                    <text>by entities in
				the initial accreditation or certification, and the re-accreditation and
				re-certification, of such opioid treatment programs;</text>
									</subclause>
                </clause>
                <clause id="idFB7A4F7BC550459AB8D8CC718DCA3DDA">
                  <enum>(ii)</enum>
                  <text>a model policy
				for dispensing methadone to be used by pharmacists that dispense methadone,
				which should include education and training guidelines for such
				pharmacists;</text>
								</clause>
                <clause id="id5B4F0BBBEDEB4DDD97074F9F2F638A1C">
                  <enum>(iii)</enum>
                  <text>the continuing education guidelines that all prescribers shall comply with in order to meet <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1524">Drug Enforcement Administration</cato:entity-ref> certification and re-certification requirements, as set forth in <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                      <cato:entity-ref entity-type="act" value="Controlled Substances Act/s:303/ss:g/p:3">section 303(g)(3) of the Controlled Substances Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/21/823/g/3">21 U.S.C. 823(g)(3)</cato:entity-ref>)</cato:entity>, which should include a minimum of 16 training hours at least every 3 years that include the integration of both addiction and pain management curricula; and</text>
								</clause>
                <clause id="id7AB016E1A6A3431EA73FCCB350152BB4">
                  <enum>(iv)</enum>
                  <text>patient
				education guidelines for both opioid treatment programs and pain management,
				including recommendations for patient counseling prior to and during opioid
				addiction treatment or treatment for pain.</text>
								</clause>
              </subparagraph>
              <subparagraph id="idF64EE45441D34D108FD5B1ED4CB800FB">
                <enum>(B)</enum>
                <header>Updating of
				guidelines</header>
                <text>Not later than 1 year after the publication of guidelines under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:506D/ss:b/p:2/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>, and at least annually thereafter, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Controlled Substances Clinical Standards Commission" proposed="true">Commission</cato:entity-ref> shall update the guidelines published under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:506D/ss:b/p:2/sp:A/cl:iii" proposed="true">clauses (iii)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:506D/ss:b/p:2/sp:A/cl:iv" proposed="true">(iv) of such subparagraph</cato:entity-ref>.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="id0C8B5D14F0D047C0BACA15DE3FC8DC8D">
              <enum>(3)</enum>
              <header>Consultation</header>
              <text>In developing and publishing the guidelines under this section, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Controlled Substances Clinical Standards Commission" proposed="true">Commission</cato:entity-ref> shall consult with relevant professional organizations with expertise in the area of addiction, relevant professional organizations with expertise in the area of pain management, physician groups, pharmacy groups (including the National Association of Boards of Pharmacy), patient representatives, and any other organization that the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> determines is appropriate for purposes of this section.</text>
						</paragraph>
          </subsection>
          <subsection id="id7EE272E10E6741AA8190255136B1F7F7">
            <enum>(c)</enum>
            <header>Website</header>
            <text>Not later than 180 days after the date of enactment of this section, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Controlled Substances Clinical Standards Commission" proposed="true">Commission</cato:entity-ref> shall establish and operate a <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Controlled Substances Clinical Standards Commission" proposed="true">Commission</cato:entity-ref> website.</text>
					</subsection>
          <subsection id="idFA34D7760FDF4D3DB43EF609997402EB">
            <enum>(d)</enum>
            <header>Methadone
				toolkit</header>
            <text>Not later than 1 year after the date of enactment of this section, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Controlled Substances Clinical Standards Commission" proposed="true">Commission</cato:entity-ref> shall establish, and distribute to practitioners that are registered to prescribe or otherwise dispense methadone, a methadone toolkit. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Controlled Substances Clinical Standards Commission" proposed="true">Commission</cato:entity-ref> shall make the components of the toolkit that are available in electronic form available on the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Controlled Substances Clinical Standards Commission" proposed="true">Commission</cato:entity-ref> website.</text>
					</subsection>
          <subsection id="id5F8478B680644F7F9202493CEA1B70D8">
            <enum>(e)</enum>
            <header>Practitioner
				education program</header>
            <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Controlled Substances Clinical Standards Commission" proposed="true">Commission</cato:entity-ref> shall develop a practitioner education program that shall be used for the practitioner education described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Controlled Substances Act/s:303/ss:g/p:3" proposed="true">section 303(g)(3) of the Controlled Substances Act</cato:entity-ref>, and shall make such program available to providers of such practitioner education.</text>
					</subsection>
          <subsection id="id87BBF9BF2F274942A47CDFAD3C64D041">
            <enum>(f)</enum>
            <header>Authorization
				of appropriations</header>
            <text>
              <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="auth-auth-approp">There is authorized to be appropriated <cato:property name="purpose">to carry
				out <cato:entity-ref entity-type="act" value="Public Health Service Act/s:506D" proposed="true">this section</cato:entity-ref>
                </cato:property> <cato:funds-and-year amount="indefinite" year="2014, 2015, 2016, 2017, 2018">such sums as may be necessary for each of fiscal years 2014
				through
				2018</cato:funds-and-year>.</cato:entity>
            </text>
					</subsection>
        </section>
        <after-quoted-block>.</after-quoted-block>
      </quoted-block>
		</section>
    <section id="idDE4ED8D3457646659D48F322536F565C">
      <enum>8.</enum>
      <header>Prescription
			 monitoring program</header>
      <text display-inline="no-display-inline">
        <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Public Health Service Act/s:399O">Section 399O of the Public Health Service Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/42/280g–3">42 U.S.C. 280g–3</cato:entity-ref>)</cato:entity> is amended—</text>
			<paragraph id="id1D4DB72D3A0A45248C514CCCF88DE554">
        <enum>(1)</enum>
        <text>in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:399O/ss:d/p:1">subsection (d)(1)</cato:entity-ref>, by inserting <quote>(including prescribers of methadone)</quote> after <quote>dispensers</quote>;</text>
			</paragraph>
      <paragraph id="idCFE83CF4C4F9424BBCBDDF3F1ADB954F">
        <enum>(2)</enum>
        <text>in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:399O/ss:e">subsection
			 (e)</cato:entity-ref>, by adding at the end the following:</text>
				<quoted-block display-inline="no-display-inline" id="id9919F365AB9846168ACF6222893E724D" style="OLC">
					<paragraph id="idBC3925D7DA5C4AD4B4CFA19980CEBC1A">
            <enum>(5)</enum>
            <text>Subject to the requirements of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:543">section 543</cato:entity-ref>, the State shall, at the request of a Federal, State, or local officer whose duties include enforcing laws relating to drugs, provide to such officer information from the database relating to an individual who is the subject of an active drug-related investigation conducted by the officer's employing government entity.</text>
					</paragraph>
          <after-quoted-block>;
				and</after-quoted-block>
        </quoted-block>
			</paragraph>
      <paragraph id="id7FD85E5C75764AA3AA3194AC0C0972EF">
        <enum>(3)</enum>
        <text display-inline="yes-display-inline">by striking <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:399O/ss:n">subsection (n)</cato:entity-ref> and inserting the following:</text>
				<quoted-block display-inline="no-display-inline" id="idD07E0DCD222E4651AF63A63CC74A5FCB" style="OLC">
					<subsection id="id7E3E33671C9F49D994EDFB0C2263F3A5">
            <enum>(n)</enum>
            <header>Appropriations</header>
            <text>
              <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="auth-auth-approp">There
				is authorized to be appropriated <cato:property name="purpose">to carry out <cato:entity-ref entity-type="act" value="Public Health Service Act/s:399O" proposed="true">this section</cato:entity-ref>
                </cato:property> <cato:funds-and-year amount="25000000" year="2014, 2015, 2016, 2017, 2018">$25,000,000 for each
				of fiscal years 2014 through 2018</cato:funds-and-year>.</cato:entity>
            </text>
					</subsection>
          <after-quoted-block>.
				</after-quoted-block>
        </quoted-block>
			</paragraph>
    </section>
    <section id="id4EB9E6C26F474EA99E3411161DFFD884">
      <enum>9.</enum>
      <header>Mortality
			 reporting</header>
      <text display-inline="no-display-inline">
        <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Public Health Service Act/t:V/pt:A">Part A of title V of the Public Health Service Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/42/290aa/etseq">42 U.S.C. 290aa et seq.</cato:entity-ref>)</cato:entity>, as amended by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Prescription Drug Abuse Prevention and Treatment Act of 2013/s:7" proposed="true">section 7</cato:entity-ref>, is further amended by adding at the end the following:</text>
			<quoted-block display-inline="no-display-inline" id="id39BE3ADBEC0842438776903B13088374" style="OLC">
				<section id="id52EA840E9BB8427E8405097136831280">
          <enum>506E.</enum>
          <header>Mortality
				reporting</header>
					<subsection id="id015C5B75EBD94C42A6C811C6A7236031">
            <enum>(a)</enum>
            <header>Model Opioid
				Treatment Program Mortality Report</header>
						<paragraph id="id8632F7DB0C3246DE8D1D20F76B786E19">
              <enum>(1)</enum>
              <header>In
				general</header>
              <text>Not later than July 1, 2014, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, acting through the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7522">Administrator</cato:entity-ref>, shall require that a Model Opioid Treatment Program Mortality Report be completed and submitted to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7522">Administrator</cato:entity-ref> for each individual who dies while receiving treatment in an opioid treatment program.</text>
						</paragraph>
            <paragraph id="id5EE4D6A5E4A049D8AB7AFA6E9581C2D3">
              <enum>(2)</enum>
              <header>Requirement of
				States that receive funding for the Controlled Substance Monitoring
				Program</header>
              <text>As a condition for receiving funds under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:399O" proposed="true">section 399O</cato:entity-ref>, each State shall require that any individual who signs a death certificate where an opioid drug is detected in the body of the deceased, or where such drug is otherwise associated with the death, report such death to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7522">Administrator</cato:entity-ref> by submitting a Model Opioid Treatment Program Mortality Report described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:506E/ss:a/p:3" proposed="true">paragraph (3)</cato:entity-ref>. Such report shall be submitted to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7522">Administrator</cato:entity-ref> on or before the later of—</text>
							<subparagraph id="id352FE1BD92494EF8977270922B844C99">
                <enum>(A)</enum>
                <text>90 days after the
				date of signing the death certificate; or</text>
							</subparagraph>
              <subparagraph id="id5DCA868CE5344B519F605E6F600CD2FD">
                <enum>(B)</enum>
                <text>as soon as practicable after the date on which the necessary postmortem and toxicology reports become available to such individual, as required by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="id99B936AB6B9240C9AC3538024A218E51">
              <enum>(3)</enum>
              <header>Development</header>
              <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7522">Administrator</cato:entity-ref>, in consultation with State and local medical examiners, prescribing physicians, hospitals, and any other organization that the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7522">Administrator</cato:entity-ref> determines appropriate, shall develop a Model Opioid Treatment Program Mortality Report to be used under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:506E/ss:a/p:1" proposed="true">paragraphs (1)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:506E/ss:a/p:2" proposed="true">(2)</cato:entity-ref>.</text>
						</paragraph>
          </subsection>
          <subsection id="id2BCA92D39F0E4576B1266606AD7AF25F">
            <enum>(b)</enum>
            <header>National Opioid
				Death Registry</header>
						<paragraph id="ID1f2a739080644ced857243b6788bb6cf">
              <enum>(1)</enum>
              <header>In
				general</header>
              <text>Not later than July 1, 2014, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7522">Administrator</cato:entity-ref> shall establish and implement, through the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="National Center for Health Statistics" entity-parent-id="7523">National Center for Health Statistics</cato:entity-ref>, a National Opioid Death Registry (referred to in this subsection as the <term>Registry</term>) to track opioid-related deaths and information related to such deaths.</text>
						</paragraph>
            <paragraph id="ID8cd2d312ea3345b498fea4c27c0d01a6">
              <enum>(2)</enum>
              <header>Consultation</header>
              <text>In establishing the uniform reporting criteria for the Registry, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7523">Director of the Centers for Disease Control and Prevention</cato:entity-ref> shall consult with the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7522">Administrator</cato:entity-ref>, State and local medical examiners, prescribing physicians, hospitals, and any other organization that the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7523">Director</cato:entity-ref> determines is appropriate for purposes of this subsection.</text>
						</paragraph>
            <paragraph id="idEAA47D33A4A74961806F4AE1BCD07435">
              <enum>(3)</enum>
              <header>Requirements</header>
              <text>The
				registry shall be designed as a uniform reporting system for opioid-related
				deaths and shall require the reporting of information with respect to such
				deaths, including—</text>
							<subparagraph id="idA9B5BC551DA84AA4BFA29D5FEA0FCEB4">
                <enum>(A)</enum>
                <text>the particular
				drug formulation used at the time of death;</text>
							</subparagraph>
              <subparagraph id="id809587A7CEEB487C98551C643052BC81">
                <enum>(B)</enum>
                <text>the dosage
				level;</text>
							</subparagraph>
              <subparagraph id="idEBCDD848620B48A6B9625180886614E7">
                <enum>(C)</enum>
                <text>a description of
				the circumstances surrounding the death in relation to the recommended dosage
				involved;</text>
							</subparagraph>
              <subparagraph id="id15EED006DBF145738485055B7C05E21B">
                <enum>(D)</enum>
                <text>a disclosure of
				whether the medication involved can be traced back to a physician’s
				prescription;</text>
							</subparagraph>
              <subparagraph id="idD7BD925A70F240228CB6EBEDF0286CCA">
                <enum>(E)</enum>
                <text>a disclosure of
				whether the individual was in an opioid treatment program at the time of
				death;</text>
							</subparagraph>
              <subparagraph id="id2F7926D101E64A14A415BEE6CADB14F3">
                <enum>(F)</enum>
                <text>the age and sex
				of the individual; and</text>
							</subparagraph>
              <subparagraph id="id1CDB36F3692D41908EF01A262813AD34">
                <enum>(G)</enum>
                <text>other
				non-personal information such as that included in filed National Association of
				Medical Examiners Pediatric Toxicology Registry case reports as required under
				the privacy standard for the de-identification of health information pursuant
				to the regulations contained in part 164 of title 45, Code of Federal
				Regulations.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="id8214AC608DDA42A0BD12A0711781545E">
              <enum>(4)</enum>
              <header>Authorization</header>
              <text>
                <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="auth-auth-approp">There
				is authorized to be appropriated <cato:funds-and-year amount="5000000" year="2014, 2015, 2016, 2017, 2018">$5,000,000 for each of fiscal years 2014
				through 2018</cato:funds-and-year> <cato:property name="purpose">to carry out <cato:entity-ref entity-type="act" value="Public Health Service Act/s:506E/ss:a" proposed="true">this subsection</cato:entity-ref>
                  </cato:property>.</cato:entity>
              </text>
						</paragraph>
          </subsection>
          <subsection id="idADFC95B8BA7E4222B117CE2230AA75E1">
            <enum>(c)</enum>
            <header>Report on
				Registry information</header>
            <text>Not later than the January 1 of the first fiscal year beginning 2 years after the date of enactment of this section, and each January 1 thereafter, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7523">Director of the Centers for Disease Control and Prevention</cato:entity-ref> shall submit to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> a report, based on information contained in the Registry described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:506E/ss:b" proposed="true">subsection (b)</cato:entity-ref>, concerning the number of methadone-related deaths in the United States for the year for which the report is submitted.</text>
					</subsection>
        </section>
        <after-quoted-block>.</after-quoted-block>
      </quoted-block>
		</section>
    <section commented="no" display-inline="no-display-inline" id="id32541624AD144B6C8113D68920274512">
      <enum>10.</enum>
      <header>Additional
			 reporting</header>
      <text display-inline="no-display-inline">
        <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Public Health Service Act/t:V/pt:A">Part A of title V of the Public Health Service Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/42/290aa/etseq">42 U.S.C. 290aa et seq.</cato:entity-ref>)</cato:entity>, as amended by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Prescription Drug Abuse Prevention and Treatment Act of 2013/s:9" proposed="true">section 9</cato:entity-ref>, is further amended by adding at the end the following:</text>
			<quoted-block display-inline="no-display-inline" id="id074E0CC2DA634AFAB1F59D34AE936BED" style="OLC">
				<section commented="no" display-inline="no-display-inline" id="idE5E2CC3B27B948B9A9D7CB8BEAED0376">
          <enum>506F.</enum>
          <header>Additional
				reporting</header>
					<subsection id="id59980A02D240416C91C956DB7404CEC2">
            <enum>(a)</enum>
            <header>Report on
				methadone usage</header>
						<paragraph id="idE33AB94AA27E4CD39A01BB1ADFBA6B8B">
              <enum>(1)</enum>
              <header>In
				general</header>
              <text>Not later than January 1 of the first fiscal year beginning 2 years after the date of enactment of this section, and each January 1 thereafter, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7522">Administrator</cato:entity-ref> and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Commissioner of Food and Drugs</cato:entity-ref> shall submit to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> a report containing detailed statistics on methadone usage for opioid treatment and pain management. Such statistics shall include—</text>
							<subparagraph id="id59F4BB8916F342F387EA73E76C19113E">
                <enum>(A)</enum>
                <text>information on
				the distribution of prescribed doses of methadone at federally qualified health
				centers, opioid treatment clinics, other health-related clinics, physician
				offices, pharmacies, and hospitals; and</text>
							</subparagraph>
              <subparagraph id="idB81469312685436EAED0AC5B1BB12D85">
                <enum>(B)</enum>
                <text>information
				relating to adverse health events resulting from such methadone usage.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="idE2E05BEB397549BCADCA22B389DFDC34">
              <enum>(2)</enum>
              <header>Availability of
				information</header>
              <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall make the reports submitted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:506F/ss:a/p:1" proposed="true">paragraph (1)</cato:entity-ref> available to the general public, including through the use of the Internet website of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Department of Health and Human Services</cato:entity-ref>.</text>
						</paragraph>
          </subsection>
          <subsection id="ID953458547dab4e5a9cc55ec5a17686b4">
            <enum>(b)</enum>
            <header>Annual report
				on effectiveness</header>
            <text>Not later than September 30, 2014, and annually thereafter until September 30, 2016, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall submit to the appropriate committees of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref>, a report concerning the effectiveness of the methadone maintenance therapy program. Such report shall evaluate the success of efforts to reduce opioid addiction and methadone-related deaths, including the impact of health care provider and patient education.</text>
					</subsection>
          <subsection id="id1B68E08FC35A4488906608168A769A0A">
            <enum>(c)</enum>
            <header>Authorization
				of appropriations</header>
            <text>
              <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="auth-auth-approp">There is authorized to be appropriated <cato:property name="purpose">to carry
				out <cato:entity-ref entity-type="act" value="Public Health Service Act/s:506F" proposed="true">this section</cato:entity-ref>
                </cato:property> <cato:funds-and-year amount="indefinite" year="2014, 2015, 2016, 2017, 2018">such sums as may be necessary for each of fiscal years 2014
				through
				2018</cato:funds-and-year>.</cato:entity>
            </text>
					</subsection>
        </section>
        <after-quoted-block>.</after-quoted-block>
      </quoted-block>
		</section>
    <section commented="no" display-inline="no-display-inline" id="idCFB72A171D1D44EBA87CB9827B0DF90D">
      <enum>11.</enum>
      <header>Development of
			 prescription drug abuse prevention and treatment quality measures across each
			 relevant provider setting</header>
      <text display-inline="no-display-inline">
        <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Public Health Service Act/t:IX/pt:D/spt:I">Subpart I of part D of title IX of the
			 Public Health Service Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/42/299b–31/etseq">42 U.S.C. 299b–31 et seq.</cato:entity-ref>)</cato:entity> is amended by adding at
			 the end the following:</text>
			<quoted-block display-inline="no-display-inline" id="id9624C5A3F29D4E0C9061E7D787CB874C" style="OLC">
				<section commented="no" display-inline="no-display-inline" id="id13FB78DA79AC4A7487D55A48B1C75DF4">
          <enum>932.</enum>
          <header>Development of
				prescription drug abuse prevention and treatment quality measures across each
				relevant provider setting</header>
					<subsection id="id557833bf8bbe4ef5aef44b0e1c77509b">
            <enum>(a)</enum>
            <header>In
				general</header>
            <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, acting through the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7528">Director of the Agency for Healthcare Research and Quality</cato:entity-ref> and in consultation with the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7523">Director of the Centers for Disease Control and Prevention</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7522">Administrator of the Substance Abuse and Mental Health Services Administration</cato:entity-ref>, and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7530">Director of the Centers for Medicare &amp; Medicaid Services</cato:entity-ref>, shall require the development and application of specific prescription drug abuse prevention and treatment quality measures for each relevant health care provider setting, as identified by the Director.</text>
					</subsection>
          <subsection id="id5DDC1E84F0044E7EB73DA5F9F3354F51">
            <enum>(b)</enum>
            <header>Dissemination</header>
            <text>Not later than April 1, 2016, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall disseminate the quality measure requirements developed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:932/ss:a" proposed="true">subsection (a)</cato:entity-ref> to all affected providers.</text>
					</subsection>
          <subsection id="idF6AD1B2CE10E4196B5DD965708008CA3">
            <enum>(c)</enum>
            <header>Types of
				measures</header>
            <text>Quality measures developed under this section may be
				structure-oriented (such as the required presence of a hospital-based treatment
				program), process-oriented (such as requiring patients to be informed of the
				addictive qualities of the medication being prescribed), or outcome-oriented
				(such as assessing family satisfaction with
				care).</text>
					</subsection>
        </section>
        <after-quoted-block>.</after-quoted-block>
      </quoted-block>
		</section>
  </legis-body>
</bill>
</doc>